Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_assertion type Assertion NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_head.
- NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_assertion description "[The TOV-21G, TOV-81D, OV-90, and TOV-112D cell lines were derived from ovarian tumors (TOV) or ascites (OV) from chemotherapy- and radiotherapy-naive patients and were characterized by their mutation spectrum of BRCA2, TGFbeta-RII, KRAS2, TP53, and CDKN2A.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_provenance.
- NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_assertion evidence source_evidence_literature NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_provenance.
- NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_assertion SIO_000772 15258697 NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_provenance.
- NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_assertion wasDerivedFrom befree-2016 NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_provenance.
- NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_assertion wasGeneratedBy ECO_0000203 NP452435.RAlZscItAgGZjMEdet7nwfKbmKG3A0EFny6hgUGoljLFw130_provenance.